Abstract 324P
Background
HLX10, a fully humanized IgG4 monoclonal antibody against the programmed death-1 (PD-1) receptor blocking PD-1, increased functional activities of human T-cells and showed in-vitro antitumour activity in xenograft models. The combined inhibition of PD-1 and VEGFR pathways may enhance a sustained suppression of cancer-related angiogenesis and tumour growth. Here, we present the phase 1 study data of HLX10 and the development of HLX10 as targeted combination immunotherapy.
Methods
We conducted an open-label, dose-finding with Bayesian optimal interval adaptive design study to evaluate safety, maximum tolerated dose, PK and clinical activity of HLX10 in patients with advanced or metastatic solid tumours refractory to standard therapy. Patients (pts) received biweekly i.v. infusions of HLX10 at doses of 0.3, 1, 3 and 10 mg/kg until disease progression, intolerable toxicities or withdrawal from the study. The dose-limiting toxicities were observed for 28 days after treatment. Clinical response was evaluated every 8 weeks for the first 24 weeks followed by every 12 weeks. Safety, PK and clinical response evaluations were performed throughout the study.
Results
As of 27-June-2019, 16 pts were dosed with HLX10 at various doses and maintained >90% PD1 receptor occupancy on the peripheral T-cells. Among 13 pts being evaluated for efficacy, 2 pts each at 0.3 and 3 mg/kg cohorts achieved stable disease; 1 pt at 3 mg/kg cohort achieved partial response with the longest follow-up time of 220 days. No infusionrelated reaction or additional safety signal was observed up to 10 mg/kg. The PK profiles demonstrated dose proportional manner as shown in the table.Table:
324P The PK parameters of 0.3 mg/kg and 3 mg/kg cohorts
Dose(mg/kg) | Cmax (μg/mL) | AUC0-t (h* μg/mL) | t1/2 (h) | |||
---|---|---|---|---|---|---|
- | C1D1 | C3D1 | C1D1 | C3D1 | C1D1 | C3D3 |
0.3 | 5.3 | 6.3 | 702.1 | 957.1 | 183.4 | 183.0 |
3 | 74.8 | 117.2 | 10823.6 | 27750.9 | 259.7 | 489.81 |
Conclusions
HLX10 is well tolerated, shows promising antitumour activities with durable objective responses in various cancers, and exhibits similar PK results to pembrolizumab and nivolumab. HLX10 is currently being tested in the first China combo-immunotherapy studies with HLX04 (a bevacizumab biosimilar) in advanced solid tumours with the longest follow-up time of > 200 days as of 20-June-2019 and in first-line treatment of metastatic NSCLC.
Clinical trial identification
HLX10-001(Registration Number: NCT0346875) monotherapy in advanced solid tumours; HLX10HLX04-001(Registration Number: NCT03757936) combo-immunotherapy in advanced solid tumours; HLX10-002-NSCLC301(Registration Number: NCT03952403) combo-immunotherapy in NSCLC.
Editorial acknowledgement
Legal entity responsible for the study
Shanghai Henlius Biotech, Inc; Taiwan Henlix Biotech., Co.,LTD.
Funding
Shanghai Henlius Biotech, Inc.
Disclosure
T.Y. Chao: Research grant / Funding (institution): Taiwan Henlix Biotech., Co., LTD. C.L. Ho: Research grant / Funding (institution): Taiwan Henlix Biotech., Co., LTD. W.H. Cheng: Research grant / Funding (institution): Taiwan Henlix Biotech., Co., LTD. C.L. Chang: Research grant / Funding (institution): Taiwan Henlix Biotech., Co., LTD. Y.Y. Hsieh: Research grant / Funding (institution): Taiwan Henlix Biotech., Co., LTD. W. Jiang: Full / Part-time employment: Shanghai Henlius Biotech, Inc. S. Liu: Full / Part-time employment: Shanghai Henlius Biotech,Inc. A. LUK: Full / Part-time employment: Shanghai Henlius Biotech, Inc. S.F. Lin: Full / Part-time employment: Taiwan Henlix Biotech., Co., LTD. T.C. Hsieh: Full / Part-time employment: Taiwan Henlix Biotech., Co., LTD. E. Liu: Full / Part-time employment: Taiwan Henlix Biotech., Co., LTD.
Resources from the same session
143P - NOTCH3 expression predicts poor survival in advanced esophageal squamous cell cancers
Presenter: Raja Pramanik
Session: Poster display session
Resources:
Abstract
144P - Severe hypovitaminosis D in metastatic gastric cancer patients from the Northern and Southern hemispheres: Data from the EXPAND phase III trial
Presenter: Radka Obermannova
Session: Poster display session
Resources:
Abstract
145P - Role of Glasgow prognostic score in chemo-naïve patients with advanced biliary tract cancer and good performance status
Presenter: Toshikazu Moriwaki
Session: Poster display session
Resources:
Abstract
146P - Anatomic versus non-anatomic resection for hepatocellular carcinoma: A meta-analysis of high-quality studies
Presenter: Bin Zhang
Session: Poster display session
Resources:
Abstract
147P - Clinical outcomes of proximal gastrectomy versus total gastrectomy for locally advanced proximal gastric cancer: a propensity score matching analysis
Presenter: Yingtai Chen
Session: Poster display session
Resources:
Abstract
148P - Efficacy of capecitabine and oxaliplatin versus S-1 as adjuvant chemotherapy in gastric cancer after D2 lymph node dissection according to lymph node ratio and N stage
Presenter: Seunghwan Lee
Session: Poster display session
Resources:
Abstract
150P - A Phase Ib Study of IMU-131 HER2/neu peptide vaccine plus chemotherapy in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction
Presenter: Yee Chao
Session: Poster display session
Resources:
Abstract
151P - Gene expression profiling for a better understanding of gastric cancer: From the perspective of metabolic rearrangement
Presenter: Midie Xu
Session: Poster display session
Resources:
Abstract
152P - Long-term outcomes of three-dimensional conformal radiotherapy-based and intensity-modulated radiotherapy-based concurrent chemoradiotherapy in patients with thoracic esophageal squamous cell carcinoma
Presenter: Chia-Lun Chang
Session: Poster display session
Resources:
Abstract
153P - Exosomal LINC00174 facilitates epithelial-mesenchymal transition in residual hepatocellular carcinoma after insufficient radiofrequency ablation by regulating c-JUN/MYCBP/c-Myc axis
Presenter: Dening Ma
Session: Poster display session
Resources:
Abstract